Genenta Science (NASDAQ:GNTA) Shares Down 3.4% – Should You Sell?

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA)’s share price was down 3.4% on Friday . The company traded as low as $1.35 and last traded at $1.68. Approximately 396,405 shares were traded during trading, a decline of 80% from the average daily volume of 2,012,488 shares. The stock had previously closed at $1.74.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genenta Science in a research note on Thursday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Genenta Science has an average rating of “Sell”.

Genenta Science Stock Down 3.4%

The business’s fifty day moving average price is $2.89 and its 200 day moving average price is $3.48.

Institutional Trading of Genenta Science

Hedge funds and other institutional investors have recently modified their holdings of the stock. Allianz SE lifted its stake in shares of Genenta Science by 126.2% in the 1st quarter. Allianz SE now owns 233,550 shares of the company’s stock valued at $927,000 after acquiring an additional 130,300 shares during the last quarter. Algebris UK Ltd raised its position in Genenta Science by 122.2% in the first quarter. Algebris UK Ltd now owns 100,000 shares of the company’s stock valued at $368,000 after purchasing an additional 55,000 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Genenta Science during the third quarter valued at about $41,000. Institutional investors own 15.13% of the company’s stock.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.